$4.5M for Excelimmune

Xconomy Boston — 

Excelimmune, a Woburn, MA-based developer of drugs made with human recombinant polyclonal antibodies, has raised $4.5 million of a planned $9 million round of equity financing, according to an SEC filing. The document did not specify the investors in the deal. The company, founded in 2006, took in $1 million in Series B funding in February to advance development of Staphguard, an experimental drug for staph infections that are immune to the antibiotic methicillin.